148.1-38m sodium, an RNA aptamer, inhibits HIV-1 reverse transcriptase (RT) and interfere with viral replication.

Calderasib (MK-1084) is a selective KRAS G12C inhibitor demonstrating antitumor efficacy. It can be utilized as monotherapy or in combination with pembrolizumab () for oncology research.

Cephalexin (hydrochloride, Cefalexin hydrochloride) is a potent, orally active cephalosporin antibiotic with broad-spectrum activity. It acts by binding to penicillin-binding proteins (PBPs), thereby disrupting bacterial cell wall synthesis. Cephalexin hydrochloride demonstrates antibacterial activity against a wide variety of gram-positive and gram-negative bacteria.

Emzadirib, an inhibitor of RAD51, exhibits a reduction in RAD51 foci. This compound displays significant anti-tumor activity with tumor growth inhibition in in vivo and in vitro models.

Ribociclib succinate hydrate is an orally bioavailable and selective, inhibitor of both CDK4 and CDK6 with IC50 values of 10 nM and 39 nM, respectively. It exhibits anticancer activitiy and can be used in breast cancer, melanoma, liposarcoma, non–small cell lung cancer, and neuroblastoma therapy research.

PolQi2 is a PolΘ inhibitor that specifically targets the N-terminal helicase domain of PolΘ, thereby suppressing alt-EJ (alternative end-joining) repair. This compound improves the accuracy and integration efficiency of gene editing across multiple loci and diverse cell lines. Additionally, it demonstrates synergistic effects with DNA-PK inhibitors in reducing Cas9-mediated off-target activity. Its application is suitable for gene editing studies.

RMC5127 is a first-in-class, orally bioavailable mutant-selective tri-complex inhibitor of the GTP-bound (ON) form of RASG12V. It non-covalently binds to cyclophilin A (CypA), forming a binary complex that engages RASG12V(ON) to form a high-affinity tri-complex, sterically inhibiting RAS binding. It inhibits the RAS pathway in KRASG12V-mutant cancer cells, reducing proliferation, inducing apoptosis, and showing strong potential for use in RASG12V-mutated cancer research.

TNG348 is an orally bioavailable allosteric inhibitor targeting the ubiquitin-specific protease USP1. It selectively and potently blocks USP1 activity, preventing deubiquitination of proliferative PCNA and FANCD2, which disrupts DNA repair mechanisms. TNG348 demonstrates inhibitory effects against BRCA1/2-mutated and homologous recombination-deficient (HRD) breast and ovarian cancers .

BI033 is a selective inhibitor of BTB and CNC homology 1 (BACH1) specifically binds to BACH1's N-terminal with a Kd of 9.0 uM. It disrupts the BACH1–HDAC1 interaction, enhances H3K27 acetylation at BACH1 target genes, and upregulates angiogenic genes, suggesting its therapeutic potential for myocardial infarction and ischemic vascular disease.

Peptide 4 is a complex synthetic peptide molecule commonly used as a research chemical or therapeutic agent due to its potential to mimic biological peptides and modulate specific molecular targets.

CT1113 is a potent dual inhibitor of USP25 and USP28 that effectively reduces c-MYC levels and exhibits strong anti-tumor activity. It can be used in research on colon and pancreatic cancers.

Taurolithocholic acid is a taurine-conjugated tertiary bile acid. It induces apoptosis in hepatoma cell lines via caspase-3/7 activation and serves as a model to study the endocrine and metabolic roles of bile acids in enterohepatic circulation and liver physiology.

Vicadrostat (compound 29 A) is a potent and selective inhibitor of aldosterone synthase(CYP11B2) with an IC50 of 16 nM. It exhibits potential in renal disease, diabetic nephropathy, cardiovascular diseases and fibrotic disorder research.

PB94 is a potent and selective inhibitor of HDAC11 with an IC50 of 108 nM and exhibits >40-fold selectivity over other HDAC isoforms. It ameliorates neuropathic pain in mouse models and can be radiolabeled with carbon-11 as [¹¹C]this compound for PET imaging, demonstrating significant brain uptake and potential for in vivo imaging applications.

SKLB-11A is a selective, first-in-class allosteric activator of SIRT3 that binds with a Kd of 4.7 μM and enhances its deacetylase activity with EC50 of 21.95 μM. It improves cardiac function and alleviates myocardial damage in vivo.

BIEGi-1 is a potent and selective binary inhibitor of EGFR that effectively blocks EGFR-catalyzed nucleotide exchange and disrupts the EGFR–Rheb interaction. It robustly inhibits both EGFR kinase activity and mTORC1 signaling in EGFR-mutant cancer cells. This compound exhibits significant anti-proliferative effects with an IC50 of 17 nM for PC9 and 20 nM for HCC827.

BSJ-5-63 is a potent PROTAC degrader of CDK12, CDK7, CDK9. BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K, while also suppressing the mRNA expression of BRCA1 and BRCA2. BSJ-5-63 demonstrates anticancer properties and has the potential for the research of prostate cancer.

VL-422 is an ionizable cationic lipid. VL-422 delivers CRISPR complementary single-guide RNA (sgRNA) and Cas9 mRNA to enable in vitro and in vivo gene editing. LNPs containing VL-422 loaded with Cas9 mRNA and sgRNA targeting the ANGPTL3 gene induce the deletion of premature stop codons within the ANGPTL3 gene in the liver of cynomolgus monkeys. Loss-of-function of ANGPTL3 leads to decreased levels of LDL, HDL and cholesterol in plasma. The VL-422 delivery system can be used for the research of gene editing strategies targeting lipid metabolism diseases.

Disclosed in PCT patent WO2025/240833A1 from Acuitas Therapeutics Inc., Compound I‑1 is a trivalent tri-GalNAc PEGylated targeting lipid composed of three ASGPR-binding GalNAc moieties, a PEG spacer and double C18 alkyl lipid tails that insert into LNP lipid bilayer.

Emvistegrast is a quinolone derivative. Emvistegrast is an antagonist of α4β7 integrin. Emvistegrast can be studied in research for diseases that are mediated by α4β7 integrin, such as infkammatory bowel disease.

DSS6-PEG-DSPE,DSPE-PEG-DSS6 is a composite molecule composed of phospholipids(DSPE),polyethylene glycol(PEG),and bone targeting peptide DSS6,mainly used for bone targeted drug delivery and bone tissue repair. Its core structure achieves precise targeting and efficient delivery through the synergistic effect of three parts.The DSS6 peptide consists of six Asp-Ser-Ser amino acid repeat sequences and can specifically recognize hydroxyapatite(HAp)in bone tissue.

WEHI-7326 (WEHI 7326) is a specifi mitotic inhibitor and potential anticancer agent, causes cell cycle arrest in G2/M, cell death in vitro (MDA-MB-231 IC50=24.4 nM), and displays efficacious anti-tumor activity in vivo.WEHI-7326 induces cell death in a broad range of cancer cell lines, including taxane-resistant cells, and inhibits growth of human colon, brain, lung, prostate and breast tumors in mice xenografts.WEHI-7326 exceeded potency of myoseverin B by almost ten-fold, did not show any significant cytotoxic activity in vitro (IC50>40 uM) in HepG2 cells.WEHI-7326 prolongs survival in mouse models of high-risk neuroblastoma and leads to complete tumor regression when used in combination with standard-of-care relapse therapies.

DSG-PEG2K-triGalNAc is a functionalized PEG lipid that enhances targeted drug delivery by binding to the Asialoglycoprotein Receptor (ASGPR) which are predominantly found on the surface of liver cells. By functionalizing DSG-PEG2K with triGalNac, it allows this PEG lipid to be used in the formation of liposomes or LNPs that target the liver for drug delivery.

MitoSOX Red is a live cell fluorescent probe that specifically targets mitochondria and is cell membrane permeable. MitoSOX Red enters mitochondria and is oxidized by superoxide but not by other ROS or RNS generating systems. The oxidized MitoSOX Red then binds to nucleic acids in mitochondria/nucleus, producing strong red fluorescence.

Anhydrotetracycline hydrochloride, a tetracycline biosynthetic precursor, is a potent competitive broad-spectrum tetracycline destructase enzymes inhibitor.

N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC50 = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC50 = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration.

A nonsteroidal selective estrogen receptor modulator (SERM) that shows 10- to 60-fold increased affinity for the estrogen receptor compared with Tamoxifen.

1400W dihydrochloride is a slow, tight binding, potent and highly selective inhibitor of inducible nitric oxide synthase (Kd = 7 nM).

Biperiden (KL 373) is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system.

Chlorisondamine (diiodide) is a potent nicotinic acetylcholine receptor (nAChR) antagonist and a ganglion blocker. Chlorisondamine antagonizes some of nicotine's central actions in a potent, long-lasting and pharmacologically selective way.